MorphoSys Takes MOR202 Back From Celgene, Will Seek New Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
MorphoSys is putting on a brave face after Celgene handed back rights to its anti-CD38 monoclonal antibody MOR202, saying it will carry on with current trials in multiple myeloma patients and voicing confidence it can find another commercial partner “once the time is right.”